Global COVID-19 Drug Associated APIs Market Report 2021 - Opportunities And Strategies, Market Forecast And Trends

Check out TBRC’s sale today for

The COVID-19 drug-associated APIs market consists of sales of active pharmaceutical ingredients used in the manufacturing of COVID-19 drugs. The active pharmaceutical ingredients are chemicals which are responsible for pharmacological activity in the human body and are used as a base in pharmaceutical drug or medicine. The APIs used for the preparation of COVID-19 drugs and include Azithromycin, Fentanyl, Albuterol, Cisatracurium and others.

Global COVID-19 Drug Associated APIs Market Size And Drivers:

The global COVID-19 drug associated APIs market is expected to grow from $4.73 billion in 2020 to $5.09 billion in 2021 at a compound annual growth rate (CAGR) of 7.6%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The COVID-19 drug-associated APIs market is expected to reach $6.66 billion in 2025 at a CAGR of 7%. High demand for some antiretrovirals, antimalarials, sedatives, bronchodilators, and other respiratory drugs drives the demand for the active pharmaceutical ingredients (APIs) used in the production of COVID-19 drugs.

Request For A Sample For The Global COVID-19 Drug Associated APIs Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3248&type=smp

Trends In The Global COVID-19 Drug Associated APIs Market

Key players operating in the pharmaceutical industry that manufactures COVID-19 drug associated APIs are focusing on strategies such as plant capacity or production capacity expansion to meet the increasing demand due to the rising number of coronavirus cases across the globe. For instance, in March 2020, Alembic Pharmaceuticals Ltd announced that the company is ramping up the production for the company’s production for azithromycin to 20 tons per month. Likewise, In April 2020, FUJIFILM Corporation announced the expansion of its manufacturing capacity and increase in the production of influenza antiviral Avigan Tablet (Favipiravir) by nearly 2.5 times by the end of July. Avigan is currently undergoing clinical trials testing its safety and efficacy for the treatment of COVID-19 patients.

Global COVID-19 Drug Associated APIs Market Segments:
The global COVID-19 drug associated APIs market is further segmented –
By Drug Class: Antimalarials, Bronchodilators, Antibiotics, Antivirals, Others
By Geography: The global COVID-19 drug associated APIs market is segmented into North America, South America, Asia-Pacific, Eastern Europe, Western Europe, Middle East and Africa.

Read More On The Report For The Global COVID-19 Drug Associated APIs Market At:

COVID-19 Drug Associated APIs Global Market Report 2021 is one of a series of new reports from The Business Research Company that provides COVID-19 drug associated APIs market overviews, analyzes and forecasts market size and growth for the global COVID-19 drug associated APIs market, COVID-19 drug associated APIs market share, COVID-19 drug associated APIs market players, COVID-19 drug associated APIs market segments and geographies, COVID-19 drug associated APIs market’s leading competitors’ revenues, profiles and market shares. The COVID-19 drug associated APIs market report identifies top countries and segments for opportunities and strategies based on market trends and leading competitors’ approaches.